Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Stock Competitors & Peer Comparison
See VRTX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VRTX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VRTX | $519.51 | +0.79% | 131.9B | 27.31 | $19.03 | N/A |
| REGN | $793.74 | +1.57% | 81.8B | 17.40 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $990.54 | +0.62% | 61.6B | 89.40 | $11.08 | N/A |
| MRNA | $146.69 | +1.89% | 58.2B | -18.00 | -$8.15 | N/A |
| RVMDW | $11.44 | +1.33% | 44.5B | -1.29 | -$8.82 | N/A |
| RVMD | $205.11 | +0.66% | 43.6B | -23.26 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $353.83 | +2.11% | 37.8B | 62.29 | $5.68 | N/A |
| ALNY | $249.99 | +0.53% | 33.5B | 45.04 | $5.55 | N/A |
Stock Comparison
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
VRTX vs REGN Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, REGN has a market cap of 81.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while REGN trades at $793.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas REGN's P/E ratio is 17.40. In terms of profitability, VRTX's ROE is +0.23%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VRTX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
VRTX vs VRNA Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VRTX's ROE is +0.23%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, VRTX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
VRTX vs ARGX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ARGX trades at $990.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ARGX's P/E ratio is 89.40. In terms of profitability, VRTX's ROE is +0.23%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, VRTX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
VRTX vs MRNA Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, MRNA has a market cap of 58.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while MRNA trades at $146.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas MRNA's P/E ratio is -18.00. In terms of profitability, VRTX's ROE is +0.23%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, VRTX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
VRTX vs RVMDW Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RVMDW has a market cap of 44.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RVMDW trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, VRTX's ROE is +0.23%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, VRTX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
VRTX vs RVMD Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RVMD trades at $205.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RVMD's P/E ratio is -23.26. In terms of profitability, VRTX's ROE is +0.23%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, VRTX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
VRTX vs SGEN Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRTX's ROE is +0.23%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRTX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
VRTX vs ONC Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ONC has a market cap of 37.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ONC trades at $353.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ONC's P/E ratio is 62.29. In terms of profitability, VRTX's ROE is +0.23%, compared to ONC's ROE of +0.14%. Regarding short-term risk, VRTX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
VRTX vs ALNY Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ALNY has a market cap of 33.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ALNY trades at $249.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ALNY's P/E ratio is 45.04. In terms of profitability, VRTX's ROE is +0.23%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, VRTX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
VRTX vs ROIV Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ROIV has a market cap of 29.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ROIV trades at $41.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ROIV's P/E ratio is -39.02. In terms of profitability, VRTX's ROE is +0.23%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, VRTX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
VRTX vs INSM Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, INSM has a market cap of 27.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while INSM trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas INSM's P/E ratio is -30.49. In terms of profitability, VRTX's ROE is +0.23%, compared to INSM's ROE of -1.11%. Regarding short-term risk, VRTX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
VRTX vs BNTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, BNTX has a market cap of 24.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while BNTX trades at $98.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas BNTX's P/E ratio is -12.82. In terms of profitability, VRTX's ROE is +0.23%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, VRTX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
VRTX vs INCY Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, INCY has a market cap of 24.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while INCY trades at $122.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas INCY's P/E ratio is 16.42. In terms of profitability, VRTX's ROE is +0.23%, compared to INCY's ROE of +0.30%. Regarding short-term risk, VRTX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
VRTX vs UTHR Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, UTHR has a market cap of 21.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while UTHR trades at $502.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas UTHR's P/E ratio is 17.99. In terms of profitability, VRTX's ROE is +0.23%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, VRTX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
VRTX vs BGNE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRTX's ROE is +0.23%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, VRTX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
VRTX vs GMAB Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, GMAB has a market cap of 20B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while GMAB trades at $32.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas GMAB's P/E ratio is 24.60. In terms of profitability, VRTX's ROE is +0.23%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, VRTX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
VRTX vs DNA-WT Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRTX's ROE is +0.23%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, VRTX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
VRTX vs ASND Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ASND trades at $264.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ASND's P/E ratio is -109.47. In terms of profitability, VRTX's ROE is +0.23%, compared to ASND's ROE of +1.90%. Regarding short-term risk, VRTX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
VRTX vs NBIX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, NBIX has a market cap of 15.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while NBIX trades at $157.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas NBIX's P/E ratio is 22.72. In terms of profitability, VRTX's ROE is +0.23%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, VRTX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
VRTX vs JAZZ Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while JAZZ trades at $245.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas JAZZ's P/E ratio is 9.17. In terms of profitability, VRTX's ROE is +0.23%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, VRTX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check JAZZ's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
VRTX vs SMMT Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while SMMT trades at $18.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas SMMT's P/E ratio is -16.45. In terms of profitability, VRTX's ROE is +0.23%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, VRTX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
VRTX vs BBIO Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while BBIO trades at $72.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas BBIO's P/E ratio is -19.35. In terms of profitability, VRTX's ROE is +0.23%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, VRTX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
VRTX vs EXEL Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while EXEL trades at $56.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas EXEL's P/E ratio is 16.06. In terms of profitability, VRTX's ROE is +0.23%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, VRTX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
VRTX vs BMRN Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, BMRN has a market cap of 12.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while BMRN trades at $66.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas BMRN's P/E ratio is 31.93. In terms of profitability, VRTX's ROE is +0.23%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, VRTX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check BMRN's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
VRTX vs HALO Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while HALO trades at $107.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas HALO's P/E ratio is 20.14. In terms of profitability, VRTX's ROE is +0.23%, compared to HALO's ROE of +1.81%. Regarding short-term risk, VRTX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
VRTX vs KRTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRTX's ROE is +0.23%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRTX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
VRTX vs MDGL Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while MDGL trades at $540.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas MDGL's P/E ratio is -42.19. In terms of profitability, VRTX's ROE is +0.23%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, VRTX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
VRTX vs ARWR Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ARWR has a market cap of 11.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ARWR trades at $80.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ARWR's P/E ratio is -35.85. In terms of profitability, VRTX's ROE is +0.23%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, VRTX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
VRTX vs TECH Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TECH trades at $72.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TECH's P/E ratio is 37.25. In terms of profitability, VRTX's ROE is +0.23%, compared to TECH's ROE of +0.09%. Regarding short-term risk, VRTX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
VRTX vs RNAM Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VRTX's ROE is +0.23%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VRTX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
VRTX vs AXSM Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while AXSM trades at $216.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas AXSM's P/E ratio is -56.55. In terms of profitability, VRTX's ROE is +0.23%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, VRTX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
VRTX vs KRYS Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while KRYS trades at $340.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas KRYS's P/E ratio is 42.61. In terms of profitability, VRTX's ROE is +0.23%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VRTX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
VRTX vs RXDX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRTX's ROE is +0.23%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRTX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
VRTX vs PTGX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while PTGX trades at $147.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas PTGX's P/E ratio is 143.48. In terms of profitability, VRTX's ROE is +0.23%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, VRTX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
VRTX vs KYMR Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while KYMR trades at $114.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas KYMR's P/E ratio is -35.82. In terms of profitability, VRTX's ROE is +0.23%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, VRTX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
VRTX vs PRAX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while PRAX trades at $330.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas PRAX's P/E ratio is -25.58. In terms of profitability, VRTX's ROE is +0.23%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, VRTX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
VRTX vs NUVL Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas NUVL's P/E ratio is -21.79. In terms of profitability, VRTX's ROE is +0.23%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VRTX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check NUVL's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
VRTX vs CYTK Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CYTK trades at $72.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CYTK's P/E ratio is -10.03. In terms of profitability, VRTX's ROE is +0.23%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, VRTX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CYTK's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
VRTX vs CRNX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CRNX's P/E ratio is -16.86. In terms of profitability, VRTX's ROE is +0.23%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VRTX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CRNX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
VRTX vs TXG Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TXG has a market cap of 8.9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TXG trades at $70.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TXG's P/E ratio is -118.83. In terms of profitability, VRTX's ROE is +0.23%, compared to TXG's ROE of -0.09%. Regarding short-term risk, VRTX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TXG's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
VRTX vs IBRX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while IBRX trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas IBRX's P/E ratio is -8.63. In terms of profitability, VRTX's ROE is +0.23%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, VRTX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
VRTX vs IMGN Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRTX's ROE is +0.23%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VRTX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
VRTX vs PCVX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while PCVX trades at $59.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas PCVX's P/E ratio is -7.80. In terms of profitability, VRTX's ROE is +0.23%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, VRTX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PCVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
VRTX vs IONS Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, IONS has a market cap of 8.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while IONS trades at $51.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas IONS's P/E ratio is -29.91. In terms of profitability, VRTX's ROE is +0.23%, compared to IONS's ROE of -1.11%. Regarding short-term risk, VRTX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IONS's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
VRTX vs TWST Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TWST has a market cap of 8.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TWST trades at $134.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TWST's P/E ratio is -60.70. In terms of profitability, VRTX's ROE is +0.23%, compared to TWST's ROE of -0.30%. Regarding short-term risk, VRTX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TWST's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
VRTX vs BPMC Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRTX's ROE is +0.23%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VRTX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
VRTX vs APGE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas APGE's P/E ratio is -31.19. In terms of profitability, VRTX's ROE is +0.23%, compared to APGE's ROE of -0.30%. Regarding short-term risk, VRTX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check APGE's competition here
Abivax S.A. (NASDAQ: ABVX)
VRTX vs ABVX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ABVX trades at $113.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ABVX's P/E ratio is -59.54. In terms of profitability, VRTX's ROE is +0.23%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VRTX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ABVX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
VRTX vs TGTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TGTX trades at $54.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TGTX's P/E ratio is 19.57. In terms of profitability, VRTX's ROE is +0.23%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, VRTX is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
VRTX vs CERE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRTX's ROE is +0.23%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VRTX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
VRTX vs SYRE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while SYRE trades at $90.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas SYRE's P/E ratio is -46.56. In terms of profitability, VRTX's ROE is +0.23%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, VRTX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
VRTX vs IMVT Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, IMVT has a market cap of 7.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while IMVT trades at $37.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas IMVT's P/E ratio is -13.35. In terms of profitability, VRTX's ROE is +0.23%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, VRTX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
VRTX vs MTSR Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VRTX's ROE is +0.23%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, VRTX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
VRTX vs CAI Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CAI trades at $26.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CAI's P/E ratio is 73.19. In terms of profitability, VRTX's ROE is +0.23%, compared to CAI's ROE of +0.19%. Regarding short-term risk, VRTX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
VRTX vs RYTM Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RYTM trades at $102.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RYTM's P/E ratio is -32.94. In terms of profitability, VRTX's ROE is +0.23%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, VRTX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
VRTX vs BLTE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while BLTE trades at $173.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas BLTE's P/E ratio is -92.51. In terms of profitability, VRTX's ROE is +0.23%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, VRTX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
VRTX vs MRUS Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VRTX's ROE is +0.23%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, VRTX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
VRTX vs ACLX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VRTX's ROE is +0.23%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VRTX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
VRTX vs RETA Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRTX's ROE is +0.23%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRTX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
VRTX vs CGON Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CGON trades at $73.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CGON's P/E ratio is -27.43. In terms of profitability, VRTX's ROE is +0.23%, compared to CGON's ROE of -0.25%. Regarding short-term risk, VRTX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
VRTX vs CNTA Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VRTX's ROE is +0.23%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VRTX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CNTA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
VRTX vs SRRK Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, SRRK has a market cap of 6.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while SRRK trades at $51.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas SRRK's P/E ratio is -15.03. In terms of profitability, VRTX's ROE is +0.23%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, VRTX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check SRRK's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
VRTX vs TVTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TVTX trades at $65.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TVTX's P/E ratio is -146.20. In terms of profitability, VRTX's ROE is +0.23%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, VRTX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
VRTX vs DNTH Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while DNTH trades at $107.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas DNTH's P/E ratio is -25.95. In terms of profitability, VRTX's ROE is +0.23%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, VRTX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check DNTH's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
VRTX vs MIRM Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while MIRM trades at $96.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas MIRM's P/E ratio is -6.65. In terms of profitability, VRTX's ROE is +0.23%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, VRTX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MIRM's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
VRTX vs ORKA Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ORKA has a market cap of 5.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ORKA trades at $95.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ORKA's P/E ratio is -49.48. In terms of profitability, VRTX's ROE is +0.23%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, VRTX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ORKA's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
VRTX vs COGT Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while COGT trades at $33.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas COGT's P/E ratio is -15.83. In terms of profitability, VRTX's ROE is +0.23%, compared to COGT's ROE of -0.73%. Regarding short-term risk, VRTX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check COGT's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
VRTX vs XENE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, XENE has a market cap of 5.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while XENE trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas XENE's P/E ratio is -12.38. In terms of profitability, VRTX's ROE is +0.23%, compared to XENE's ROE of -0.44%. Regarding short-term risk, VRTX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
VRTX vs LGND Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while LGND trades at $280.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas LGND's P/E ratio is 30.81. In terms of profitability, VRTX's ROE is +0.23%, compared to LGND's ROE of +0.20%. Regarding short-term risk, VRTX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
VRTX vs CDTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VRTX's ROE is +0.23%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, VRTX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CDTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
VRTX vs ERAS Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ERAS trades at $16.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ERAS's P/E ratio is -17.38. In terms of profitability, VRTX's ROE is +0.23%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, VRTX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ERAS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
VRTX vs PTCT Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while PTCT trades at $66.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas PTCT's P/E ratio is -28.53. In terms of profitability, VRTX's ROE is +0.23%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, VRTX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PTCT's competition here
Abcam plc (NASDAQ: ABCM)
VRTX vs ABCM Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRTX's ROE is +0.23%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRTX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
VRTX vs ISEE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRTX's ROE is +0.23%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRTX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ISEE's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
VRTX vs DFTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, DFTX has a market cap of 5.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while DFTX trades at $40.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas DFTX's P/E ratio is N/A. In terms of profitability, VRTX's ROE is +0.23%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, VRTX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check DFTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
VRTX vs APLS Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas APLS's P/E ratio is 38.35. In terms of profitability, VRTX's ROE is +0.23%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VRTX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
VRTX vs CRSP Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CRSP trades at $52.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CRSP's P/E ratio is -11.13. In terms of profitability, VRTX's ROE is +0.23%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, VRTX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
VRTX vs EWTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while EWTX trades at $44.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas EWTX's P/E ratio is -24.12. In terms of profitability, VRTX's ROE is +0.23%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, VRTX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
VRTX vs TERN Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TERN's P/E ratio is -51.41. In terms of profitability, VRTX's ROE is +0.23%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VRTX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
VRTX vs ACAD Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ACAD trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ACAD's P/E ratio is 12.40. In terms of profitability, VRTX's ROE is +0.23%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, VRTX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ACAD's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
VRTX vs FOLD Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VRTX's ROE is +0.23%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VRTX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
VRTX vs AKRO Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VRTX's ROE is +0.23%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, VRTX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
VRTX vs ALPN Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRTX's ROE is +0.23%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VRTX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check ALPN's competition here
Veradermics, Incorporated (NYSE: MANE)
VRTX vs MANE Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while MANE trades at $101.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas MANE's P/E ratio is -32.36. In terms of profitability, VRTX's ROE is +0.23%, compared to MANE's ROE of -0.38%. Regarding short-term risk, VRTX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
VRTX vs OPT Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRTX's ROE is +0.23%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VRTX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
VRTX vs PRTC Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas PRTC's P/E ratio is -3.78. In terms of profitability, VRTX's ROE is +0.23%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, VRTX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PRTC's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
VRTX vs PBLS Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, PBLS has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while PBLS trades at $36.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas PBLS's P/E ratio is -41.09. In terms of profitability, VRTX's ROE is +0.23%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, VRTX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check PBLS's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
VRTX vs RLAY Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RLAY trades at $19.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RLAY's P/E ratio is -12.14. In terms of profitability, VRTX's ROE is +0.23%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, VRTX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check RLAY's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
VRTX vs IOVA Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, IOVA has a market cap of 4.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while IOVA trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas IOVA's P/E ratio is -12.68. In terms of profitability, VRTX's ROE is +0.23%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, VRTX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check IOVA's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
VRTX vs MRTX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRTX's ROE is +0.23%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRTX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
VRTX vs CELC Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CELC trades at $83.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CELC's P/E ratio is -19.43. In terms of profitability, VRTX's ROE is +0.23%, compared to CELC's ROE of -3.51%. Regarding short-term risk, VRTX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check CELC's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
VRTX vs TNGX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TNGX trades at $24.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TNGX's P/E ratio is -29.57. In terms of profitability, VRTX's ROE is +0.23%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, VRTX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
VRTX vs TLX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while TLX trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas TLX's P/E ratio is 122.96. In terms of profitability, VRTX's ROE is +0.23%, compared to TLX's ROE of +0.07%. Regarding short-term risk, VRTX is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check TLX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
VRTX vs ADPT Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ADPT trades at $24.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ADPT's P/E ratio is -60.44. In terms of profitability, VRTX's ROE is +0.23%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, VRTX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ADPT's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
VRTX vs ELVN Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while ELVN trades at $54.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas ELVN's P/E ratio is -32.59. In terms of profitability, VRTX's ROE is +0.23%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, VRTX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
VRTX vs CPRX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CPRX's P/E ratio is 12.30. In terms of profitability, VRTX's ROE is +0.23%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VRTX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
VRTX vs RYZB Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRTX's ROE is +0.23%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRTX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check RYZB's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
VRTX vs AMLX Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while AMLX trades at $33.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas AMLX's P/E ratio is -22.43. In terms of profitability, VRTX's ROE is +0.23%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, VRTX is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for VRTX.Check AMLX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
VRTX vs CBAY Comparison September 2026
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRTX stands at 131.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRTX is priced at $519.51 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRTX currently has a P/E ratio of 27.31, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRTX's ROE is +0.23%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRTX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for VRTX.Check CBAY's competition here